The Efficacy of Chlorhexidine Gluconate Pre

Status Completed

Clinical Trial Summary

To test whether pre - disinfection skin scrub with 4% chlorhexidine gluconate is more effective on the reduction of surgical site microbial colonization and subsequent infection than is normal saline.

Clinical Trial Description

Surgical site infections (SSIs) following elective surgical procedures occur most commonly as a result of colonization by the patient's native skin flora . The most common pathogens causing SSIs are Staphylococcus aureus and coagulase-negative Staphylococci , components of normal skin flora . Therefore, preoperative disinfection of the surgical site with an antiseptic skin preparation is standard practice before any surgical intervention to decrease skin microbial counts before incision . It is considered an important step in limiting surgical wound contamination and preventing infection.

A variety of skin-preparation agents and methods are available for preventing surgical site infections and the techniques for preoperative cleansing of the skin vary among hospitals and surgeons. There is a pressing need to elucidate the effect of cutaneous disinfection with chlorhexidine gluconate ( CHG ) in prevention of surgical site infections.

Many studies demonstrated that comparisons with cutaneous disinfection with povidone-iodine, disinfection with CHG before insertion of an intravascular device and for post-infection site care can substantially reduce the incidence of device-related infection .

Hence, this study aimed to test whether an additional chlorhexidine gluconate scrub followed by a routine disinfection would lower the incidence of surgical site culture and subsequent infection after hepatic resection. This data will show the originality and clinical importance of a cutaneous pre-disinfection scrubbing solution for such risk patients with hepatectomy. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01782573
Study type	Interventional
Source	Changhua Christian Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	October 2011
Completion date	September 2012

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01197820` - Hepatic and Renal Thermography Using Magnetic Resonance Imaging	N/A
Terminated	`NCT00942383` - Freehand Ultrasound Elasticity Imaging in Liver Surgery
Active, not recruiting	`NCT03432806` - A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors
Completed	`NCT01403727` - Electromagnetic Tracking of Devices During Biopsy Procedures	N/A
Recruiting	`NCT00691691` - Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors	Phase 2
Terminated	`NCT00955097` - Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors	Phase 1
Recruiting	`NCT02184182` - Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS)	Phase 2
Completed	`NCT02162732` - Molecular-Guided Therapy for Childhood Cancer	N/A
Recruiting	`NCT05990257` - CMRA for US-guided-MWA of Liver Tumors	N/A
Completed	`NCT00828607` - Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses	N/A
Completed	`NCT00960609` - Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study	N/A
Completed	`NCT05445973` - Added Value of Contrast-enhanced Ultrasonography for Percutaneous Radiofrequency Ablation	N/A
Completed	`NCT03171428` - Hepatectomy With or Without the Thoraco-abdominal Approach	N/A
Completed	`NCT02509507` - Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611	Phase 1/Phase 2
Completed	`NCT00877136` - A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Recruiting	`NCT04315883` - Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors
Completed	`NCT01031784` - Radioactive Holmium Microspheres for the Treatment of Liver Metastases	Phase 1
Active, not recruiting	`NCT00845689` - Prevention of Liver Damage During Liver Surgery	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Efficacy of Chlorhexidine Gluconate Pre - Disinfection Scrubbing in Preventing Surgical Site Infections for Hepatectomy Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms